MS-DRG 838MDC 17
CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT
Related MS-DRGs in MDC 17
820LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH MCC821LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC822LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC823LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITH MCC824LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITH CC825LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC826MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH MCC827MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH CC828MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC829MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH OTHER PROCEDURES WITH CC/MCC
Frequently asked questions
What is MS-DRG 838?
CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT
What is the relative weight of MS-DRG 838?
MS-DRG 838 has a relative weight of 2.0874 for FY2026, which reflects the relative resource intensity of cases grouped into it.
What is the average length of stay for MS-DRG 838?
The geometric mean length of stay for MS-DRG 838 is 5.1 days.
What Major Diagnostic Category (MDC) does MS-DRG 838 belong to?
MS-DRG 838 falls under MDC 17: Myeloproliferative Diseases and Disorders, and Poorly Differentiated Neoplasms.
MS-DRG data (FY2026) from the CMS Inpatient Prospective Payment System (IPPS) final rule. Always verify codes with authoritative sources before making billing decisions.